Business segment information (Tables)

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Schedule of External Net Sales by SBU Reporting Segment

The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to our new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution^®, Trinity ELITE™ and Versashield™ in our Biologics segment.

	External Net Sales by SBU
	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2014		2013		Reported Growth			Constant Currency Growth
BioStim	$	38,424	$	38,242		1	%		1	%
Biologics		13,019		13,378		(3	)%		(3	)%
Extremity Fixation		27,079		26,217		3	%		4	%
Spine Fixation		22,820		25,536		(11	)%		(11	)%
Total Net Sales	$	101,342	$	103,373		(2	)%		(2	)%

Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment

The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:

Net margin by SBU	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2014			2013
Net margin:
BioStim	$	14,188		$	16,938
Biologics		6,693			6,025
Extremity Fixation		9,297			7,967
Spine Fixation		5,105			2,197
Corporate		(444	)		(425	)
Total net margin		34,839			32,702
General and administrative		17,545			18,330
Research and development		5,939			5,741
Amortization of intangible assets		584			544
Costs related to the accounting review and restatement		8,306			—
Operating income	$	2,465		$	8,087